Membranous nephropathy is a common clinical disease, and the incidence has been increasing in recent years, Membranous ? Most patients with nephropathy present with nephrotic syndrome. It is generally believed that 1/3 of patients with membranous nephropathy can spontaneously remit, 1/3 of patients remain relatively stable for a long time, and 1/3 of patients may develop into renal failure. The prognosis of membranous nephropathy is closely related to patients’ proteinuria and plasma albumin levels. At present, Western medicine treats membranous nephropathy mainly with antihypertensive drugs, hormones and immunosuppressants, which have certain effect, but also have certain side effects, such as diabetes, femoral head necrosis, gastrointestinal bleeding, cataract, glaucoma and increase the chance of infection, which bring a lot of harm to patients. We have been exploring new ideas and methods of treating membranous nephropathy mainly with Chinese medicine. In the past 5 years, we have treated 54 cases of membranous nephropathy with simple Chinese medicine (strengthening the spleen, dispelling dampness, and luo method) and conducted long course of follow-up observation. The rates of complete and partial remission at 6 months were 9.8% and 54.9%, the rates of complete and partial remission at 12 months were 23.91% and 58.70%, and the rates of complete and partial remission at 18 months were 33.33% and 54.55%, respectively, and the remission rates of patients were positively correlated with the duration of treatment. Comparing the relevant domestic and international literature, TCM does have certain advantages in the effectiveness of treatment of membranous nephropathy. The more important advantage of TCM therapy for membranous nephropathy may originate from the safety, which has less incidence of side effects. No patient in this clinical observation had femoral necrosis or diabetes mellitus, and patients had fewer infections. In terms of treatment response, the first improvement was edema, followed by an increase in plasma albumin, and then, a gradual decrease in urine protein to achieve complete or partial remission. Although this study is a single-center clinical observation, it can still have a high clinical value due to its long follow-up period and relatively complete clinical data, which can shed a high light on the treatment of membranous nephropathy.